URSO for colon cancer? ------------------------ Axcan
Pharma of Mont-Saint-Hilaire, Que., said that 25% of patients with
early-stage colon cancer taking URSO had polyp recurrence after a year of
follow-up, compared with 44% of placebo controls, in a phase-2 trial. The
average diameter of recurring polyps after one year among those taking URSO
was 0.07 cm, compared with 0.31 cm in the placebo group. The report came
after an interim analysis of 258 of 716 patients who have been randomized in
the study. URSO is approved for primary biliary cirrhoris.
